Personalized or stratifi ed medicine is the use of a patient's genotype or other molecular diagnostic (pharmacogenomic) data to guide a treatment decision. Personalized medicine is believed to hold the greatest promise in therapeutic areas such as oncology where the patient-to-patient variability in response to treatment is particularly high (among other factors).
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The rapidly falling cost and broad availability of DNA sequence data is a key technological driver of PM.
Recent policy changes by major health insurers (payers) have emphasized the importance of PM diagnostic tests in treatment selection. 3, 4 However, the commercial impact of PM has so far been modest, with relatively few examples accounting for a small share of the overall market for pharmaceuticals. Aside from the modest number of PM drugs on the market, there is very little available information on the evolution of PM and the near term potential impact of PM on clinical development and practice.
OBJECTIVES:
Targeted therapies using pharmacogenomic data promise to improve the safety, effi cacy, and cost-effectiveness of drug treatment signifi cantly. To assess research progress in targeting biopharmaceutical interventions to address unmet medical need, we investigated therapeutic, temporal, and economic trends in personalized medicine using data from a national clinical trial registry.
METHODS:
Personalized medicine (PM) is the use of a patient's genotype or other molecular diagnostic (pharmacogenomic) data to guide a treatment decision. We queried ClinicalTrials.gov for studies using pharmacogenomic criteria for inclusion or exclusion, or for stratifying outcomes, restricting our analysis to Phase III or IV studies initiated on or before January 7, 2009. We verified the sensitivity of our search strategy using a known set of studies for which PM-related trials have been conducted.
RESULTS:
1.7% (N=155) of registered Phase III/IV trials in the US (N=9,111) used pharmacogenomic data. Over time, the number of trials using pharmacogenomic data has increased greatly and, as expected, most PM trials (55%) were in the therapeutic areas of oncology and hematology. However, we observed a marked increase in the number of PM trials for drugs targeting disorders with highly variable treatment response, such as neurology and mental health disorders including Alzheimer's, depression, and schizophrenia. In addition, we found that the source of funding for PM trials increasingly comes from the pharmaceutical industry rather than from public sources.
CONCLUSION:
Targeting drugs to smaller subgroups is assumed to result in treating those patients most likely to respond and least likely to experience an adverse event. These data are consistent with the idea that these gains will be experienced broadly across therapeutic areas, however, the degree of impact will vary according to our understanding of the molecular basis of disease, with associated implications for assessing relative clinical and cost effectiveness.
In order to assess research progress in targeting biopharmaceutical interventions to address unmet medical need, we investigated therapeutic, temporal, and economic trends in personalized medicine using data from a national clinical trial registry.
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Data were consistent with the idea that in the future gains from PM will be experienced more broadly across therapeutic areas, with underlying demand a function of several factors including variability in treatment response and unmet need.
Advances in clinical development of PM appears to also follow advances in the scientific understanding of the molecular basis of disease, with potential implications for assessing relative clinical and cost effectiveness.
Research into personalized medicine will continue to gain importance to payers, particularly in areas with high-cost specialty therapeutics, and also as the cost for genetic testing and other sophisticated diagnostic methods continues to fall.
DISCUSSION/LIMITATIONS
Growth in the number of Phase III PM trials appeared to level off after 2003, while the number of Phase IV trials continued to increase (see Figure 2) . This increase over time suggests that products already on the market may become subject to additional PM testing. It may also refl ect the value of retrospective studies to investigate differential effi cacy or safety, whether sponsored by pharmaceutical industry or other funding sources.
Sensitivity of search terms was only tested in an oncology setting; key terms from other therapeutic areas may have been omitted.
Registration on ClinicalTrials.gov is not compulsory for privately-funded trials, therefore the proportion of privately-funded studies may be underestimated.
Trends are not adjusted for the total number of trials registered each year (period and cohort trends may be misrepresented). 
Study Design
ClinicalTrials.gov was queried for studies using pharmacogenomic criteria for inclusion or exclusion, or for stratifying outcomes.
Analysis was restricted to Phase III or IV studies initiated on or before January 7, 2009 and conducted in the United States.
Search terms were compiled from pharmacogenomic literature.
The list of search terms (and associated phrases) included: biologic marker (biomarker, markers, signature molecule), overexpression (overexpress), overexpressing, expression (expressed), expressing, mutation (DNA alteration, gene alteration, genetic alteration, genetic chance, molpath.mut, mutated, mutations, sequence alteration), genotype (genotyping), receptor, genetic, express, and snp (single nucleotide polymorphism, snp info).
Sensitivity of the search strategy was validated using a known set of breast cancer studies for which PM-related trials have been conducted.
Statistical Analysis
Results were categorized by therapeutic area, stratifi cation marker, inclusion/ outcome criteria, and safety/response endpoints.
Simple descriptive statistics were used to identify therapeutic, economic, temporal, and trial characteristic trends.
Trends in PM over time were analyzed using the start year of each clinical trial (see Figures 2, 3 , and 5).
RESULTS
Figure 1: Identifi cation of Relevant Trials
We identifi ed 9,111 Ph III or Ph IV trials that met the initial inclusion criteria.
Of these, 155 (1.7%) were identifi ed as PM-related. Among the identifi ed trials, a few conditions represented the majority of those observed in CNS/neurology/behavioral, and oncology/hematology therapeutic areas. PM-related trials for depression or schizophrenia, and breast cancer were most prevalent within their respective therapeutic areas. Dermatology (1) Gastrointestinal (3) Oncology/Hematology (85) Ophthalmology (2) Renal ( 
